Cagrilintide

Cagrilintide is a novel, long-acting acylated amylin analogue designed for research into metabolic regulation and weight management. It functions as a non-selective agonist for both amylin receptors (AMYR) and calcitonin G protein-coupled receptors (CTR), mimicking the physiological effects of the endogenous hormone amylin. By targeting these pathways, Cagrilintide is investigated for its potential to induce satiety, delay gastric emptying, and regulate glucose homeostasis, particularly in the context of obesity and type 2 diabetes.